Healthcare Services

Neurofibromatosis Type 1 Market Expansion Outlook Through 2030 With Revenue Growth Insights

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Value Trend Is Expected For The Neurofibromatosis Type 1 Market From 2026 To 2030?

The market size for neurofibromatosis type 1 has shown substantial growth in recent years. It is anticipated to increase from $8.83 billion in 2025 to $9.68 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.6%. This historical expansion can be linked to factors like the prompt identification of NF1 symptoms, the development of effective pain management treatments, a rise in the diagnosis of plexiform neurofibromas, the adoption of surgical tumor removal procedures, and increasing awareness of genetic counseling.

The market for neurofibromatosis type 1 is projected to experience substantial expansion over the upcoming years. This market is forecast to reach a valuation of $13.78 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.2%. Factors driving this growth during the projection period include an increasing need for targeted NF1 therapies, greater investment in precision oncology, an expansion of available treatment options for optic glioma, improved access to advanced imaging technologies, and the creation of new gene-based treatments. Key trends anticipated during the forecast encompass a heightened application of targeted therapy for shrinking tumors, a rising call for early NF1 genetic screening, the broadening of surgical approaches for tumor excision, an increased uptake of radiation therapy for optic gliomas, and a stronger emphasis on supportive care and counseling services.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21230&type=smp

What Major Growth Factors Are Impacting The Neurofibromatosis Type 1 Market?

The neurofibromatosis type 1 (NF1) market is projected to experience growth propelled by spontaneous (de novo) mutations. A spontaneous (de novo) mutation refers to a genetic alteration that arises for the first time in an individual due to errors in DNA replication or environmental factors, rather than being inherited. The rise in spontaneous (de novo) mutations is attributed to increased parental age, environmental factors such as radiation and chemical exposure, and errors in DNA replication during cell division. Neurofibromatosis type 1 (NF1) contributes to spontaneous (de novo) mutations due to its high mutation rate in the NF1 gene, which frequently undergoes large deletions, insertions, or point mutations during gametogenesis, leading to new cases without a family history. For instance, in August 2023, according to a report published by Molecular Biology and Evolution, a US-based peer-reviewed journal, 1.17 million autosomal and pseudoautosomal variants, averaging 11,007 variants per offspring, passed the Mendelian violation filter. Among these, 534 putative de novo mutations (DNMs) were identified in POR and TVA families, excluding those shared among siblings. Therefore, spontaneous (de novo) mutation is a key driver for the growth of the neurofibromatosis type 1 (NF1) market.

Which Segment Divisions Form The Structure Of The Neurofibromatosis Type 1 Market?

The neurofibromatosis type 1 market covered in this report is segmented –

1) By Treatment: Medication, Surgery, Radiation Therapy, Other Treatments

2) By Disease Type: Plexiform Neurofibromas, Cutaneous Neurofibromas, Optic Gliomas, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Medication: Targeted Therapy, Pain Management Medications, Anticonvulsants

2) By Surgery: Tumor Removal Surgery, Nerve Decompression Surgery

3) By Radiation Therapy: Stereotactic Radiosurgery, External Beam Radiation Therapy

4) By Other Treatments: Physical Therapy, Genetic Counseling, Psychological Support And Counseling

Which Trends Are Supporting The Evolution Of The Neurofibromatosis Type 1 Market?

Leading companies within the neurofibromatosis treatment market are actively developing innovative drugs and investigational targeted therapies, such as MEK inhibitors, to maintain their market presence. A MEK inhibitor is a class of targeted therapies designed to block the MEK enzyme, a component of the MAPK signaling pathway, thereby assisting in the treatment of cancers and genetic disorders like neurofibromatosis by suppressing cell growth and tumor progression. For example, in March 2024, SpringWorks Therapeutics, Inc., a US-based biopharmaceutical company, completed its new drug application submission to the FDA for Mirdametinib, intended for the treatment of both children and adults with NF1-PN. Mirdametinib functions as a selective MEK inhibitor specifically engineered to target pathways involved in the growth of neurofibromas. The FDA’s review process will evaluate the safety and efficacy of this treatment, offering the potential to considerably improve outcomes for individuals affected by NF1-PN.

Who Are The Prominent Players Across The Neurofibromatosis Type 1 Market?

Major companies operating in the neurofibromatosis type 1 market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, BeiGene Ltd, BioMarin Pharmaceutical Inc, Blueprint Medicines Corporation, SpringWorks Therapeutics Inc, Healx Limited, Infixion Bioscience Limited, NFlection Therapeutics Inc, Pasithea Therapeutics Corporation, Mulberry Biotherapeutics Inc, CureAge Therapeutics, Fosun Pharmaceutical Group Co Ltd, AstraZeneca Plc, Genentech Inc, Regeneron Pharmaceuticals Inc, Amgen Inc, AbbVie Inc, GL Pharm Tech Corporation, ReCode Therapeutics Inc.

Access The Complete Neurofibromatosis Type 1 Market Report:

https://www.thebusinessresearchcompany.com/report/neurofibromatosis-type-1-global-market-report

Which Region Leads The Neurofibromatosis Type 1 Market By Size?

North America was the largest region in the neurofibromatosis type 1 (NF1) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurofibromatosis type 1 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Neurofibromatosis Type 1 Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21230&type=smp

Browse Through More Reports Similar to the Global Neurofibromatosis Type 1 Market 2026, By The Business Research Company

Fibromyalgia Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/fibromyalgia-treatment-global-market-report

Rare Neurological Disease Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Uterine Fibroids Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/uterine-fibroids-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795